ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

OSIP: Osi Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

OSI PHARMACEUTICALS INC (NASD)
OSIP	32.79	-0.07	(-0.21%)	Vol. 346,990	16:00 ET

Osi Pharmaceuticals is one of the leading pharmaceutical research and development organizations, commercializing its skills in drug discovery, preclinical research, and drug development. The company has assembled an effective drug discovery and development capability comprised of a talented team of research scientists and business professionals.

General Information

OSI PHARMA INC

41 Pinelawn Road Melville, NY 11747 Phone: 631 962-2000 Fax: 631 752-3880 Web: www.osip.com Email: investor_info@osip.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/18/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	32.86
52 Week High	43.00
52 Week Low	27.01
Beta	0.64
20 Day Moving Average	682,875.63
Target Price Consensus	42.18

% Price Change
4 Week	1.30
12 Week	-3.98
YTD	-16.03

% Price Change Relative to S&P 500
4 Week	0.20
12 Week	-9.48
YTD	-30.50

Share Information
Shares Outstanding (millions)	58.03
Market Capitalization (millions)	1,902.67
Short Ratio	5.53
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.41
Current Year EPS Consensus Estimate	1.26
Estimated Long-Term EPS Growth Rate	15.20
Next EPS Report Date	02/18/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.14
30 Days Ago	2.14
60 Days Ago	2.14
90 Days Ago	2.14

Fundamental Ratios

P/E
Current FY Estimate:	25.94
Trailing 12 Months:	16.48
PEG Ratio	1.71

EPS Growth
vs. Previous Year	39.29%
vs. Previous Quarter	178.57%

Sales Growth
vs. Previous Year	17.84%
vs. Previous Quarter:	12.50%

Price Ratios
Price/Book	2.80
Price/Cash Flow	13.40
Price / Sales	4.73

ROE
09/30/09	18.57
06/30/09	20.80
03/31/09	33.05

ROA
09/30/09	10.51
06/30/09	10.62
03/31/09	14.19

Current Ratio
09/30/09	10.94
06/30/09	13.45
03/31/09	15.51

Quick Ratio
09/30/09	10.65
06/30/09	13.11
03/31/09	15.10

Operating Margin
09/30/09	29.16
06/30/09	27.74
03/31/09	33.40

Net Margin
09/30/09	28.87
06/30/09	30.23
03/31/09	33.41

Pre-Tax Margin
09/30/09	28.87
06/30/09	30.23
03/31/09	33.41

Book Value
09/30/09	11.72
06/30/09	11.28
03/31/09	10.78

Inventory Turnover
09/30/09	0.47
06/30/09	0.51
03/31/09	0.47

Debt-to-Equity
09/30/09	0.56
06/30/09	0.58
03/31/09	0.60

Debt to Capital
09/30/09	35.83
06/30/09	36.51
03/31/09	37.37


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research